Furthermore, the interaction between CTCF and hypoxia-responsive pathways, such as those governed by hypoxia-inducible factors (HIFs) 40, may unveil novel mechanisms underlying tumor progression and resistance to therapeutic interventions. Here, CTCF is linked to neoplasm.